Management of Major Bleeding with the Non-Vitamin K Oral Anticoagulants: the Role of Antidotes

摘要: Over the recent years, new oral anticoagulant agents have been developed and entered clinical arena, direct or non-vitamin K anticoagulants (NOACs). Although more expensive, these proven as equivalent superior to vitamin antagonists in treatment of non-valvular atrial fibrillation (AF) venous thrombo-embolism with a lower incidence intracerebral hemorrhage. Nevertheless, occurrence major life-threatening bleeding events is still quite possible. Thus, there concern regarding lack specific antidote rapid reversal agent such disastrous situations. Fortunately, development effective NOAC antidotes has recently made great advances, which are herein briefly reviewed.